|
|
Stable Emulsion (SE) vaccine adjuvant |
|
Vaxjo ID |
197 |
|
Vaccine Adjuvant Name |
Stable Emulsion (SE) vaccine adjuvant |
|
Alternative Names |
SE |
|
Adjuvant VO ID |
VO_0006101
|
|
Description |
emulsion vaccine adjuvant that includes squalene-based oil-in-water emulsion that induces mixed Th1/Th2 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
2 |
|
Second Host Species for Testing |
3 |
|
Components |
Shark liver squalene purchased from Sigma–Aldrich (St. Louis, MO); egg yolk phosphatidylcholine (PC) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) obtained from Avanti Polar Lipids, Inc. (Alabaster, AL); and Pluronic F-68 NF prill surfactant obtained courtesy of BASF (Florham Park, NJ). The buffer components, monobasic and dibasic ammonium phosphate, were obtained from Riedel-de Haën (Seelze, Germany) and Spectrum Chemical (Gardena, CA). Distilled water was deionized with a Barnstead E-pure for use in all formulations. Water for injection (WFI) was obtained from Abbot Laboratories (North Chicago, IL |
|
Storage |
2-8C |
|
Preparation |
Emulsions were prepared by mixing a buffered aqueous phase (ammonium phosphate buffer, detergent, glycerol) with an oil phase (squalene or Miglyol, phosphatidylcholine, optional α-tocopherol), followed by high-shear mixing and high-pressure homogenization (~30,000 psi for 12 passes). The oil phase was sonicated at ~50 °C until dissolved. Phases were combined at a 90:10 ratio and stored at 2–8 °C |
| References |
(Soza, 2025): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=84]
Vanni et al., 2022: Vanni T, Thomé BC, Sparrow E, Friede M, Fox CB, Beckmann AM, Huynh C, Mondini G, Silveira DH, Viscondi JYK, Braga PE, Silva AD, Salomão MDG, Piorelli RO, Santos JP, Gattás VL, Lucchesi MBB, Oliveira MMM, Koike ME, Kallas EG, Campos LMA, Coelho EB, Siqueira MAM, Garcia CC, Miranda MD, Paiva TM, Timenetsky MDCST, Adami EA, Akamatsu MA, Ho PL, Precioso AR. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial. PloS one. 2022; 17(10); e0274943. [PubMed: 36256646].
|
|
